Overview

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in HCV positive subjects who were classified as non-responders to previous adequate PEG-IFN plus RBV therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin